Belimumab With Rituximab for Primary Membranous Nephropathy
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2020-03-06Est. Completion: 2029-03-01
Enrollment target: 58 participants
Locations
University of Alabama at Birmingham School of Medicine: Division of Nephrology, Birmingham, Alabama, United States
University of Arkansas, Little Rock, Arkansas, United States
University of California San Francisco, San Francisco, California, United States
Stanford University School of Medicine: Division of Nephrology, Stanford, California, United States
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center:Division of Nephrology and Hypertension, Torrance, California, United States
University of Colorado, Aurora, Colorado, United States
Mayo Clinic Jacksonville: Department of Nephrology and Hypertension, Jacksonville, Florida, United States
University of Miami Miller School of Medicine, Div of Nephrology, Miami, Florida, United States
Johns Hopkins, Baltimore, Maryland, United States
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
University of Michigan, Ann Arbor, Michigan, United States
University of Minnesota Health Clinical Research Unit, Minneapolis, Minnesota, United States
Washington University in St. Louis, St Louis, Missouri, United States
Other microbiome trials you might be interested in